Group Health, Kaiser Permanente researchers in JAMA Internal Medicine
Study link: “BeneFITs” to increase colorectal cancer screening in priority populations
Seattle, WA—People living in poverty are less likely to be screened regularly for colorectal cancer—and more likely to develop the disease and die from it. How to end these disparities—and raise screening rates, lower disease rates, and prevent deaths? A promising way is to mail fecal immunochemical tests (a newer kind of stool test) to populations, Beverly B. Green, MD, MPH, and Gloria D. Coronado, PhD, wrote in the June 17 JAMA Internal Medicine.
Dr. Green is a Group Health physician and an associate investigator at Group Health Research Institute. Dr. Coronado is a senior investigator and the Mitch Greenlick endowed scientist for health disparities at Kaiser Permanente Center for Health Research, in Portland. The journal invited them to write a commentary about a study that David W. Baker, MD, MPH, of Northwestern University led and published in the same issue of the journal.
Drs. Green and Coronado applauded Baker’s study for achieving repeat screening rates of more than 82 percent in a largely low-income community. But they were disappointed that only 60 percent of individuals with a positive screening stool test completed follow-up diagnostic colonoscopy. “Lack of a follow-up colonoscopy defeats the purpose of a stool-test screening program,” said Dr. Green, who is also an assistant clinical professor at the University of Washington School of Medicine.
Previous studies have shown that when low-income people get colorectal cancer screening, they tend to prefer the option of doing a stool test in the privacy of their own home. But when the test is “positive” (detecting microscopic blood in the stool), people need to get a second test: a follow-up diagnostic colonoscopy. After a positive stool test, nearly a third of people have advanced pre-cancers that can be removed during the follow-up colonoscopy—and 4 percent have colorectal cancer.
“For many people, the barriers to receiving the needed follow-up diagnostic colonoscopy include cost,” Dr. Green said. For instance, the Affordable Care Act (ACA) mandates full coverage of screening tests that the U.S. Preventive Services Task Force (USPSTF) recommends—with no out-of-pocket expenses. But it covers only the first test that a person chooses—a stool test, colonoscopy, or sigmoidoscopy—not any follow-up diagnostic testing. That’s why Drs. Green and Coronado previously urged that the ACA be amended to cover co-pays for follow-up colonoscopies after a positive stool test or flexible sigmoidoscopy. Otherwise, people who choose those as their first tests could face high, unexpected costs from follow-up testing—and existing disparities in screening could worsen.
“On the other hand, most states’ Medicaid insurance pays for both stool testing and follow-up colonoscopy, with no out-of-pocket patient costs,” Dr. Coronado said. “So disparities in deaths from colorectal cancer could decrease rapidly in those states that have opted into Medicaid expansion.”
Dr. Green previously showed in a randomized trial that colorectal cancer screening doubled when Group Health’s electronic health record was used in a new way to identify people who needed screening and give them stepped increases in support. And Drs. Green and Coronado showed it was feasible to use a population-based program for mailing stool tests to people in safety-net clinics.
The Kaiser Permanente Center for Health Research, founded in 1964, is a nonprofit research institution dedicated to advancing knowledge to improve health. It has research sites in Portland, Ore., Honolulu, and Atlanta.
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.